|
|
| Line 3: |
Line 3: |
| | <StructureSection load='5vnv' size='340' side='right'caption='[[5vnv]], [[Resolution|resolution]] 1.40Å' scene=''> | | <StructureSection load='5vnv' size='340' side='right'caption='[[5vnv]], [[Resolution|resolution]] 1.40Å' scene=''> |
| | == Structural highlights == | | == Structural highlights == |
| - | <table><tr><td colspan='2'>[[5vnv]] is a 1 chain structure with sequence from [http://en.wikipedia.org/wiki/Synthetic_construct_sequences Synthetic construct sequences]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5VNV OCA]. For a <b>guided tour on the structure components</b> use [http://proteopedia.org/fgij/fg.htm?mol=5VNV FirstGlance]. <br> | + | <table><tr><td colspan='2'>[[5vnv]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Synthetic_construct Synthetic construct]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5VNV OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=5VNV FirstGlance]. <br> |
| - | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=1PE:PENTAETHYLENE+GLYCOL'>1PE</scene>, <scene name='pdbligand=FMT:FORMIC+ACID'>FMT</scene>, <scene name='pdbligand=K:POTASSIUM+ION'>K</scene></td></tr> | + | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 1.4Å</td></tr> |
| - | <tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[5vnw|5vnw]]</td></tr>
| + | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=1PE:PENTAETHYLENE+GLYCOL'>1PE</scene>, <scene name='pdbligand=FMT:FORMIC+ACID'>FMT</scene>, <scene name='pdbligand=K:POTASSIUM+ION'>K</scene></td></tr> |
| - | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://proteopedia.org/fgij/fg.htm?mol=5vnv FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5vnv OCA], [http://pdbe.org/5vnv PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5vnv RCSB], [http://www.ebi.ac.uk/pdbsum/5vnv PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5vnv ProSAT]</span></td></tr> | + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=5vnv FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5vnv OCA], [https://pdbe.org/5vnv PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=5vnv RCSB], [https://www.ebi.ac.uk/pdbsum/5vnv PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=5vnv ProSAT]</span></td></tr> |
| | </table> | | </table> |
| | <div style="background-color:#fffaf0;"> | | <div style="background-color:#fffaf0;"> |
| Line 22: |
Line 22: |
| | </StructureSection> | | </StructureSection> |
| | [[Category: Large Structures]] | | [[Category: Large Structures]] |
| - | [[Category: Synthetic construct sequences]] | + | [[Category: Synthetic construct]] |
| - | [[Category: Kruse, A C]] | + | [[Category: Kruse AC]] |
| - | [[Category: McMahon, C]] | + | [[Category: McMahon C]] |
| - | [[Category: Camelid]]
| + | |
| - | [[Category: De novo protein]]
| + | |
| - | [[Category: Llama]]
| + | |
| - | [[Category: Nanobody]]
| + | |
| - | [[Category: Synthetic protein]]
| + | |
| Structural highlights
Publication Abstract from PubMed
Camelid single-domain antibody fragments ('nanobodies') provide the remarkable specificity of antibodies within a single 15-kDa immunoglobulin VHH domain. This unique feature has enabled applications ranging from use as biochemical tools to therapeutic agents. Nanobodies have emerged as especially useful tools in protein structural biology, facilitating studies of conformationally dynamic proteins such as G-protein-coupled receptors (GPCRs). Nearly all nanobodies available to date have been obtained by animal immunization, a bottleneck restricting many applications of this technology. To solve this problem, we report a fully in vitro platform for nanobody discovery based on yeast surface display. We provide a blueprint for identifying nanobodies, demonstrate the utility of the library by crystallizing a nanobody with its antigen, and most importantly, we utilize the platform to discover conformationally selective nanobodies to two distinct human GPCRs. To facilitate broad deployment of this platform, the library and associated protocols are freely available for nonprofit research.
Yeast surface display platform for rapid discovery of conformationally selective nanobodies.,McMahon C, Baier AS, Pascolutti R, Wegrecki M, Zheng S, Ong JX, Erlandson SC, Hilger D, Rasmussen SGF, Ring AM, Manglik A, Kruse AC Nat Struct Mol Biol. 2018 Feb 12. pii: 10.1038/s41594-018-0028-6. doi:, 10.1038/s41594-018-0028-6. PMID:29434346[1]
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
References
- ↑ McMahon C, Baier AS, Pascolutti R, Wegrecki M, Zheng S, Ong JX, Erlandson SC, Hilger D, Rasmussen SGF, Ring AM, Manglik A, Kruse AC. Yeast surface display platform for rapid discovery of conformationally selective nanobodies. Nat Struct Mol Biol. 2018 Feb 12. pii: 10.1038/s41594-018-0028-6. doi:, 10.1038/s41594-018-0028-6. PMID:29434346 doi:http://dx.doi.org/10.1038/s41594-018-0028-6
|
